Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

Commercial planning responsibilities span XDEMVY and four investigational programs across Phase 2 and Phase 3.

Rhea-AI Summary

Tarsus Pharmaceuticals (Nasdaq: TARS) appointed Neera Clase as Chief Commercial Officer, effective November 1, 2026, following her interim service.

Clase has held the interim role since July 2026 and previously served as Senior Vice President of Market Access. She will lead commercial strategy and execution, focusing on expanding XDEMVY’s reach among eye care professionals and patients. Clase believes XDEMVY has the potential to exceed $2 billion in peak sales. Her responsibilities also include commercial planning for Phase 3 programs gildeuretinol for Stargardt disease and IRX-101 as an ocular antiseptic, plus Phase 2 programs TP-04 for ocular rosacea and TP-05 for Lyme disease prevention.

3 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Clase believes XDEMVY has the potential to exceed $2 billion in peak sales.
• Minor point. Forward-looking: it has not happened yet and may not happen.XDEMVY expansion among eye care professionals and patients will be Clase’s primary commercial focus.
• Minor point. Forward-looking: it has not happened yet and may not happen.Commercial planning will cover two Phase 3 programs and two Phase 2 programs.

Negative

• None.

Key Figures

Appointment effective date: Nov. 1, 2026

Appointment effective date

Nov. 1, 2026

Neera Clase’s appointment as Chief Commercial Officer

Key Terms

demodex blepharitis, punctate keratitis, phase 3, phase 2

4 terms

demodex blepharitis medical

"treat Demodex blepharitis by targeting and eradicating the root cause"

An inflammatory eye condition caused by tiny mites (Demodex) that live at the base of eyelashes, leading to redness, itching, crusting and chronic eyelid irritation. It matters to investors because it represents a clear clinical need that can drive demand for new drugs, medical devices and diagnostic tests; like a common household pest problem, it can create recurring treatment markets, ongoing clinical development and potential regulatory milestones that affect company value.

punctate keratitis medical

"Other ocular adverse reactions reported by less than 2% of patients"

Punctate keratitis is a condition in which many tiny, pinpoint defects appear on the cornea’s surface, often visible as small dots or abrasions under a microscope. It matters to investors because it can affect clinical trial safety assessments, product labeling, and regulatory review for eye drugs or devices—like a car with many small chips in its paint that signal broader wear or exposure concerns for a product under evaluation.

phase 3 technical

"two Phase 3 retina programs"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 2 technical

"two Phase 2 programs"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served as Tarsus’ Interim Chief Commercial Officer since July 2026 and previously served as Senior Vice President of Market Access.

“Neera has the right experience and vision to lead us into our next chapter of growth,” said Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “She has been instrumental in creating a new market for XDEMVY, building our commercial team and capabilities from the earliest days and securing the broad coverage that has made this launch a standout in eye care. She brings sound judgment, credibility and a deep understanding of our business. As Tarsus expands into retina and advances its broader pipeline, I am confident in Neera’s ability to build on XDEMVY’s success and bring future innovation to more patients.”

As Chief Commercial Officer, Ms. Clase will lead Tarsus’ commercial strategy and execution, with a primary focus on expanding XDEMVY’s reach among eye care professionals and patients. She will also lead commercial planning across one of the most differentiated pipelines in eye care: two Phase 3 retina programs – gildeuretinol (ALK-001), an investigational treatment for Stargardt disease, and IRX-101, an investigational ocular antiseptic; and two Phase 2 programs – TP-04 for ocular rosacea and TP-05 for Lyme disease prevention.

“When I joined Tarsus, we were a small team with a first-in-class medicine and a conviction that we could make a difference for millions of patients living with Demodex blepharitis,” said Ms. Clase. “Helping make XDEMVY accessible to patients has been one of the most rewarding experiences of my career. I believe XDEMVY has the potential to exceed $2 billion in peak sales by reaching more of the patients who need treatment, and delivering on that opportunity is my first priority. As our pipeline advances, I’m excited to engage new communities of physicians and patients and apply what we’ve learned with XDEMVY to the programs ahead.”

Ms. Clase has more than 25 years of biopharmaceutical experience across sales, marketing, market access, reimbursement and commercialization. Previously, she held senior commercial and market access leadership positions at Acadia Pharmaceuticals, Relypsa, Inc., and Abbott Laboratories. She has helped commercialize more than 10 products across multiple therapeutic areas, including several first-in-class therapies. She holds a Bachelor of Arts in life sciences and psychology from Indiana State University and a Master of Social Work from Indiana University.

About XDEMVY^®
XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation. XDEMVY was evaluated in two pivotal trials involving over 800 patients with twice-daily dosing for six weeks. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment-related adverse events. Most patients found the XDEMVY eye drop to be neutral to very comfortable. The most common ocular adverse reactions observed in the studies were instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported by less than 2% of patients were chalazion/hordeolum (stye) and punctate keratitis.

XDEMVY Indication and Important Safety Information

INDICATIONS AND USAGE
XDEMVY is indicated for the treatment of Demodex blepharitis.

Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

For additional information, please see full prescribing information available at https://xdemvy.com/.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2, IRX-101 for potential use as an ocular antiseptic, and gildeuretinol for the potential treatment of Stargardt disease.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the benefits of the new executive leader, the potential market size of Demodex blepharitis, advancement of Tarsus’ investigational pipeline programs, and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Further risks and uncertainties are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus' Form 10-K for the year ended December 31, 2025, filed with the SEC on February 23, 2026, and its most recent Form 10-Q filed with the SEC on August 6, 2026, copies of which are posted on its website and are available from Tarsus without charge. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:
Adrienne Kemp
Vice President, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com 

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Neera Clase become Tarsus Pharmaceuticals’ Chief Commercial Officer?

Neera Clase’s appointment becomes effective November 1, 2026. She has served as Interim Chief Commercial Officer since July 2026 and previously served as Senior Vice President of Market Access.

What peak sales potential does Tarsus’ Neera Clase see for XDEMVY?

Clase believes XDEMVY has the potential to exceed $2 billion in peak sales by reaching more patients who need treatment. This is her assessment of potential sales, not a reported sales result.